Emerging Longevity Ventures
VC Fund
Emerging Longevity Ventures is a venture capital firm.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Emerging Longevity Ventures invests in
Stages Emerging Longevity Ventures invests in
Countries Emerging Longevity Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brian Manning Delaney
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 3 (50%)
- Health Care 2 (33%)
Stage
- Seed 3 (50%)
- Funding Round 1 (17%)
Country
- United States 1 (17%)
- United Kingdom 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brian Manning Delaney
Founder
|
Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
ImmuneAGE Bio is an intriguing initiative focused on drug discovery for immune system rejuvenation. Developing therapies that can rejuvenate or enhance the immune system could have profound implications for healthcare, especially in aging populations or those with compromised immune function | $2M / Seed / Jul 11, 2024 | |
|
Senisca
|
Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M / Mar 18, 2024 | |
|
Senisca
|
Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M / Seed / Mar 18, 2024 | |
|
Senisca
|
Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $2.5M / Seed / Jun 09, 2022 | |
|
Senisca
|
Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $1.8M / Seed / Mar 05, 2021 | |
|
|
Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling humanbeings to improve their health span through targeting the causes of age-related diseases and ageing itself. | $2.2M / Seed / May 07, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Emerging Longevity Ventures invest in?
Emerging Longevity Ventures invests primarily in Biotechnology and Health Care startups, most often at Seed and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Emerging Longevity Ventures?
Public channels for Emerging Longevity Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Emerging Longevity Ventures?
The team at Emerging Longevity Ventures includes Brian Manning Delaney (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!